Blog >
+ d'info


The SPIN cohort

2 July 2019

The SPIN Cohort is a group of people with scleroderma from around the world who participate in SPIN’s online studies. Cohort participants are recruited by rheumatologists and other scleroderma healthcare providers from over 40 clinical sites in 7 countries. Through the cohort, SPIN collects information about important challenges to people with scleroderma and their support needs. Some cohort participants are also invited to test SPIN’s online support programs for scleroderma before releasing them to the public.


Click here to learn more about the cohort:


Scleroderma Quebec raises $ 240 000 for research and patient support

15 November 2016

For immediate release

Montreal, November 1st, 2016 – Scleroderma Quebec raised more than $ 240 000 during its benefit evening which was held at Montreal’s Cabaret du Casino on November 1st. The funds will be used to support patients who have scleroderma and to finance the research required to find a cure.  The event was organized under the Honorary Presidency of Mr. François Armand, RBC Royal Bank’s Regional Vice-President of Commercial Financial Services, Quebec Branch.  About 500 people attended the dinner-show starring Robert Charlebois who came back one more time this year by popular demand.

Nutrition and Recipe Book

15 November 2016

Nutrition and recipe book for people with scleroderma

It can be a challenge to know what to eat for the betterment of one’s health.  This is particularly true for those affected by the numerous symptoms of scleroderma. (more…)

Scleroderma Support Group Survey

23 April 2015

Do you have scleroderma? Are you interested in helping advance research on scleroderma support groups? If so, please lend a hand by completing this short 10-15 minute survey!  (more…)

Drug approved for the treatment of pulmonary arterial hypertension

2 October 2014

Pulmonary arterial hypertension (PAH) is a common, serious complication of Scleroderma which can quickly lead to death if left untreated. Opsumit® (macitentan) was shown to be effective in reducing morbidity and mortality in adult patients with PAH. (more…)